Nitrite does not provide additional protection to thrombolysis in a rat model of stroke with delayed reperfusion.
An adjuvant therapy to prolong the therapeutic window for stroke patients is urgently needed. This randomized, blinded, placebo-controlled study investigated adjuvant intravenous sodium nitrite with recombinant tissue plasminogen activator (rtPA) in middle cerebral artery occlusion (MCAO) with 6 and 2 h of ischemia followed by reperfusion in Sprague-Dawley rats (n=59). Quantitative diffusion, T(1)-, T(2)-weighted, and semiquantitative perfusion imaging were performed before and after reperfusion and at 48 h after ischemia to determine the spatiotemporal evolution of stroke. After 48 h animals were killed and examined to evaluate infarct size and evidence of hemorrhagic transformation. Factor VIII immunostaining was performed to assess vessel morphology. Nitrite treatment (6 h group: 37.5 micromol for more than 90 mins; 2 h group: 26.25 and 1.75 micromol for more than 60 mins) did not reduce infarct volume 48 h after MCAO compared with saline-treated placebo groups after 6 or 2 h of MCAO. Stroke progression from baseline to 48 h, based on the apparent diffusion coefficient and relative cerebral blood flow deficits before and after reperfusion and T(2)-weighted hyperintensity at 48 h, did not differ between treated and control animals. These results suggest that nitrite is not a protective adjuvant therapy to delayed rtPA administration after ischemic stroke in rats.
Schatlo
Bawarjan
B
Surgical Neurology Branch, National Institutes of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
Henning
Erica C
EC
Pluta
Ryszard M
RM
Latour
Lawrence L
LL
Golpayegani
Nahal
N
Merrill
Marsha J
MJ
Lewin
Naomi
N
Chen
Yong
Y
Oldfield
Edward H
EH
D000818:Animals; D004195:Disease Models, Animal; D008279:Magnetic Resonance Imaging; D008297:Male; D009573:Nitrites / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury; D020521:Stroke / Q000188:drug therapy*; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome
D009573:Nitrites